With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.122833-04-9,2-Methoxy-4-(4-methylpiperazin-1-yl)aniline,as a common compound, the synthetic route is as follows.
A mixture of 7-chloro-1-cyclobutyl-3-(2,6-dimethylphenyl)-3,4- dihydropyrimido[4,5-d]pyrimidin-2(1H)-one (3) (70 mg, 0.204 mmol), 2-methoxy-4-(4- methylpiperazin-1-yl)aniline (66 mg, 0.298 mmol) and TFA (0.5 mL) in n-BuOH (5 mL) was stirred at 110C overnight, the mixture was concentrated, the residue was purified by prep- HPLC (0.05%NH4HCO3in CH3CN-H20) to give YKL-06-061 as white solid (50 mg, yield 47%). LCMS (m/z): 528 [M + H]+. 1H-NMR (CDCl3 , 400 MHz): delta 8.22 (d, J = 8.4 Hz, 1H), 7.95 (s, 1H), 7.36 (s, 1H), 7.09 – 7.16 (m, 3H), 6.56 – 6.60 (m, 2H), 4.90 – 4.98 (m, 1H), 4.37 (s, 2H), 3.90 (s, 3H), 3.20 (t, J = 5.2 Hz, 4H), 2.58 – 2.68 (m, 6H), 2.46-2.54 (m, 2H), 2.38 (s, 3H), 2.23 (s, 6H), 1.74-1.89 (m, 2H).
122833-04-9, The synthetic route of 122833-04-9 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; THE GENERAL HOSPITAL CORPORATION; DANA-FARBER CANCER INSTITUTE, INC.; MURAKAMI, Ryo; FISHER, David, E.; MUJAHID, Nisma; GRAY, Nathanael, S.; (0 pag.)WO2018/160774; (2018); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics